Raloxifene 60 mg from Dragon Pharma, marketed under the brand Evista, is a selective estrogen receptor modulator (SERM) investigated for its dualistic effects on estrogen receptors. It acts as an agonist in bone tissue, supporting density and strength, while functioning as an antagonist in breast and uterine tissues. Supplied in oral tablet form, this compound is widely studied in postmenopausal models and hormone-sensitive pathways, especially regarding aging, osteoporosis, and metabolic regulation.
Mechanism of Action
Raloxifene binds with high affinity to estrogen receptors (ERα and ERβ), acting selectively based on tissue type. In bone, it mimics estrogen's protective effects by decreasing osteoclast activity and enhancing bone mineral density (BMD). In contrast, it blocks estrogenic signaling in breast and endometrial tissue, making it a subject of interest in cancer prevention models.
Its mechanism also involves changes in lipid metabolism, where it can improve LDL levels without stimulating uterine growth. Unlike traditional hormone replacement therapies (HRT), it offers a more targeted modulation, minimizing unwanted systemic estrogenic effects.
Key Features & Benefits
- SERM Activity: Exhibits tissue-specific agonist and antagonist effects on estrogen receptors.
- Bone Health Research: Studied for preserving bone density and reducing resorption in aging populations.
- Hormone Modulation: Aids in research focused on managing estrogen-sensitive conditions without full HRT.
- Oral Administration: Convenient 60 mg tablet formulation for consistent dosing in lab studies.
- Anti-Cancer Pathways: Explored for its ability to block estrogen in breast and uterine tissues in experimental models.
Legal Disclaimer
Disclaimer: Raloxifene is provided for laboratory and research use only. It is not approved for therapeutic or human consumption. Researchers must adhere to all relevant regulations and safety protocols when handling this compound.
Frequently Asked Questions
Raloxifene is a selective estrogen receptor modulator (SERM) researched for its ability to support bone strength and manage estrogen-sensitive tissues in experimental hormone studies.
It acts as an estrogen receptor agonist in bone to support density and as an antagonist in breast and uterine tissues to block estrogenic stimulation.
Some research models have shown fluid retention or shifts in fat distribution, though not universally observed. These effects may be secondary to hormonal modulation.
Hair loss is not a common outcome in controlled research settings. However, any changes in estrogen pathways can potentially influence hair cycles in sensitive subjects.
No. Raloxifene is a SERM and works differently from bisphosphonates, which directly inhibit bone-resorbing osteoclasts.
